1. Adaptive Modelling of Mutated FMO3 Enzyme Could Unveil Unexplored Scenarios Linking Variant Haplotypes to TMAU Phenotypes
- Author
-
Fabiana Nicita, Simona Alibrandi, Concetta Scimone, Antonina Sidoti, Rosalia D'Angelo, Carmela Rinaldi, and Luigi Donato
- Subjects
Adult ,Male ,Models, Molecular ,FMO3 ,TMAU ,in silico ,proteomics ,genetic variants ,In silico ,Pharmaceutical Science ,Organic chemistry ,Computational biology ,Biology ,Proteomics ,Article ,Analytical Chemistry ,symbols.namesake ,Methylamines ,QD241-441 ,Drug Discovery ,Missense mutation ,Humans ,Physical and Theoretical Chemistry ,Binding site ,Nuclear Magnetic Resonance, Biomolecular ,Sanger sequencing ,Haplotype ,Phenotype ,Chemistry (miscellaneous) ,Docking (molecular) ,Mutation ,symbols ,Oxygenases ,Molecular Medicine ,Female ,Metabolism, Inborn Errors - Abstract
Background: Trimethylaminuria (TMAU) is a rare genetic disease characterized by the accumulation of trimethylamine (TMA) and its subsequent excretion trough main body fluids, determining the characteristic fish odour in affected patients. We realized an experimental study to investigate the role of several coding variants in the causative gene FMO3, that were only considered as polymorphic or benign, even if the available literature on them did not functionally explain their ineffectiveness on the encoded enzyme. Methods: Mutational analysis of 26 TMAU patients was realized by Sanger sequencing. Detected variants were, subsequently, deeply statistically and in silico characterized to determine their possible effects on the enzyme activity. To achieve this goal, a docking prediction for TMA/FMO3 and an unbinding pathway study were performed. Finally, a TMAO/TMA urine quantification by 1H-NMR spectroscopy was performed to support modelling results. Results: The FMO3 screening of all patients highlighted the presence of 17 variants distributed in 26 different haplotypes. Both non-sense and missense considered variants might impair the enzymatic kinetics of FMO3, probably reducing the interaction time between the protein catalytic site and TMA, or losing the wild-type binding site. Conclusions: Even if further functional assays will confirm our predictive results, considering the possible role of FMO3 variants with still uncertain effects, might be a relevant step towards the detection of novel scenarios in TMAU etiopathogenesis.
- Published
- 2021
- Full Text
- View/download PDF